Close Menu

NEW YORK – Investment bank Oppenheimer on Wednesday initiated coverage on diagnostics company Bionano Genomics with a rating of Outperform and a price target of $1.50.

In a note to investors, analyst Kevin DeGeeter said the company is transitioning from selling optical mapping equipment to research labs to selling clinical diagnostics that have the potential to replace microarrays for cytogenetics analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.